Hospital
Ascension Via Christi Hospitals Wichita INC.
Ascension Via Christi Hospitals Wichita INC. was paid $8.87M by Medicaid between Jan 2018 and Nov 2024, across 188 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoASCENSION VIA CHRISTI HOSPITALS WICHITA INC.
WICHITA, KS 67214
WICHITA, KS 67214
33aNPI1154314789assigned 08/30/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.87M
24GClaims375,457
24DCodes billed188
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kansas
Rank by total paid#5 of 48
Median peer was paid$461K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 108,212 | $2.20M | |
| 2019 | 59,738 | $1.37M | |
| 2020 | 38,614 | $943K | |
| 2021 | 50,531 | $1.43M | |
| 2022 | 44,658 | $1.30M | |
| 2023 | 51,408 | $1.04M | |
| 2024incomplete | 22,296 | $579K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 58,190 | 55,069 | $2.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 52,710 | 48,775 | $2.15M |
| 87631 | 6.9% | 6,039 | 5,819 | $612K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.6% | 10,575 | 10,107 | $409K |
| 80053 | Comprehensive metabolic panel | 3.9% | 37,229 | 33,668 | $349K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 19,470 | 17,561 | $339K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.8% | 2,794 | 2,682 | $252K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 3,624 | 3,207 | $195K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 17,279 | 15,358 | $183K |
| S9485 | Crisis intervention mental health services, per diem | 1.6% | 202 | 81 | $139K |
| G0378 | Hospital observation service, per hour | 1.4% | 3,000 | 1,360 | $127K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 4,602 | 3,959 | $124K |
176 more codes
| 85027 | 1.3% | 17,097 | $116K | |
| 97597 | 1.2% | 956 | $105K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 5,033 | $103K |
| 81025 | 1.1% | 12,456 | $97K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,603 | $76K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,278 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,244 | $65K |
| 84484 | <1% | 6,579 | $60K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 870 | $57K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,035 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,634 | $40K |
| 81001 | <1% | 12,157 | $40K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 380 | $39K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 808 | $37K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 808 | $37K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,005 | $36K |
| 83690 | <1% | 4,297 | $29K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,470 | $24K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 256 | $22K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 321 | $22K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 567 | $22K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 703 | $21K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 518 | $20K |
| 87660 | <1% | 744 | $19K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 68 | $18K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,109 | $18K |
| 77336 | <1% | 353 | $15K | |
| 12001 | <1% | 78 | $14K | |
| 76801 | <1% | 183 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 74 | $10K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 249 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 148 | $10K |
| 87480 | <1% | 744 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 917 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 598 | $8K |
| 87510 | <1% | 744 | $8K | |
| 77334 | <1% | 225 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 100 | $7K |
| 93971 | <1% | 97 | $7K | |
| 77300 | <1% | 79 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 732 | $7K |
| 90899 | <1% | 168 | $6K | |
| 96376 | <1% | 391 | $6K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 41 | $6K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 145 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 925 | $6K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 200 | $6K |
| 74178 | <1% | 53 | $6K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 143 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 82 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 272 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,493 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 509 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 75 | $4K |
| 87081 | <1% | 505 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 69 | $4K |
| 80329 | <1% | 84 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 97 | $4K |
| 73630 | <1% | 227 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 51 | $4K |
| 82962 | <1% | 871 | $4K | |
| 73562 | <1% | 216 | $3K | |
| 76770 | <1% | 59 | $3K | |
| 73610 | <1% | 167 | $3K | |
| 83735 | <1% | 554 | $3K | |
| 73130 | <1% | 196 | $3K | |
| 80320 | <1% | 181 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 15 | $3K |
| 10060 | <1% | 13 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 15 | $3K |
| 87186 | <1% | 231 | $3K | |
| 81003 | <1% | 2,336 | $3K | |
| 73110 | <1% | 123 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,521 | $2K |
| 73030 | <1% | 143 | $2K | |
| 84112 | <1% | 23 | $2K | |
| 84702 | <1% | 196 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 64 | $2K |
| 72100 | <1% | 109 | $2K | |
| 74022 | <1% | 67 | $2K | |
| 87077 | <1% | 185 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 115 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,939 | $2K |
| 70486 | <1% | 16 | $2K | |
| 83605 | <1% | 187 | $2K | |
| 73502 | <1% | 60 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,940 | $1K |
| 80069 | <1% | 187 | $1K | |
| 83880 | <1% | 81 | $1K | |
| 76642 | <1% | 27 | $1K | |
| 74018 | <1% | 124 | $1K | |
| 12011 | <1% | 14 | $1K | |
| J3490 | Unclassified drugs | <1% | 363 | $993.78 |
| 86901 | <1% | 204 | $981.57 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 429 | $940.79 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 90 | $926.88 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,176 | $912.03 |
| 97162 | <1% | 24 | $836.40 | |
| 87040 | <1% | 79 | $828.68 | |
| 73080 | <1% | 47 | $819.83 | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $814.21 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 423 | $804.10 |
| 85610 | <1% | 301 | $790.38 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $654.76 |
| 97161 | <1% | 14 | $651.36 | |
| 80061 | Lipid panel | <1% | 62 | $642.24 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 382 | $602.09 |
| 73140 | <1% | 41 | $592.88 | |
| 94060 | <1% | 17 | $554.30 | |
| 87147 | <1% | 79 | $552.01 | |
| 94760 | <1% | 147 | $510.44 | |
| 87070 | <1% | 79 | $443.66 | |
| 94729 | <1% | 16 | $416.68 | |
| 82550 | <1% | 42 | $393.81 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 29 | $388.17 |
| 84100 | <1% | 72 | $341.38 | |
| 85730 | <1% | 139 | $339.59 | |
| 86850 | <1% | 61 | $339.13 | |
| 85379 | <1% | 37 | $330.84 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 571 | $309.07 |
| 86900 | <1% | 80 | $302.17 | |
| 87205 | <1% | 78 | $299.77 | |
| 82565 | <1% | 75 | $277.04 | |
| 90715 | <1% | 13 | $269.08 | |
| 87075 | <1% | 36 | $266.59 | |
| 82570 | <1% | 49 | $264.10 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 62 | $259.31 |
| 82803 | <1% | 17 | $247.71 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 15 | $237.03 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 181 | $233.40 |
| 86140 | <1% | 34 | $230.56 | |
| 73090 | <1% | 13 | $205.32 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 48 | $200.98 |
| 73590 | <1% | 13 | $198.13 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 182 | $168.08 |
| 84156 | <1% | 41 | $166.42 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 165 | $163.23 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 120 | $146.41 |
| 77470 | <1% | 15 | $140.16 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 24 | $124.80 |
| 88342 | <1% | 16 | $124.40 | |
| 82948 | <1% | 44 | $110.40 | |
| 76000 | <1% | 13 | $109.43 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 163 | $109.41 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 43 | $106.88 |
| 84550 | <1% | 13 | $88.91 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 136 | $87.96 |
| 85652 | <1% | 16 | $82.92 | |
| 82947 | <1% | 22 | $64.33 | |
| 99152 | <1% | 14 | $63.88 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 43 | $60.52 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 29 | $57.15 |
| 94150 | <1% | 62 | $41.16 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,188 | $38.82 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 173 | $32.33 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 135 | $31.41 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 21 | $30.84 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 244 | $22.42 |
| 85014 | <1% | 17 | $20.28 | |
| 85018 | <1% | 19 | $20.28 | |
| A9270 | Non-covered item or service | <1% | 9,457 | $15.73 |
| A4217 | Sterile water/saline, 500 ml | <1% | 12 | $15.69 |
| 36415 | Collection of venous blood by venipuncture | <1% | 268 | $12.00 |
| J2704 | Injection, propofol, 10 mg | <1% | 112 | $5.72 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 52 | $5.32 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 212 | $2.46 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 19 | $1.18 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 19 | $0.56 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 16 | $0.00 |
| 36600 | 0% | 16 | $0.00 | |
| 94726 | 0% | 15 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 16 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 18 | $0.00 |
| C1769 | Guide wire | 0% | 39 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEGNER, MICHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Catholic Health Initiatives-Iowa Corp. | Des Moines, IA | $628K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.